Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

KIO 104

Next Previous
X
Search
Drug Profile

KIO 104

Alternative Names: KIO-104

Latest Information Update: 09 Sep 2024

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Kiora Pharmaceuticals
  • Class Anti-inflammatories; Eye disorder therapies; Small molecules
  • Mechanism of Action Dihydroorotate dehydrogenase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Uveitis
  • New Molecular Entity Yes

Highest Development Phases

  • Phase I/II Uveitis
  • Preclinical Proliferative vitreoretinopathy

Most Recent Events

  • 04 Sep 2024 Preclinical trials in Proliferative vitreoretinopathy in USA (Intravitreous) prior to September 2024 (Kiora Pharmaceuticals pipeline, September 2024)
  • 21 Aug 2023 Kiora Pharmaceuticals anticipates to discuss the development path for KIO 104 in posterior non-infectious Uveitis with the US FDA in a type 2 pIND meeting in Q3 2024
  • 21 Aug 2023 Kiora Pharmaceuticals plans to pursue Orphan Drug Designation for KIO 104 for posterior non-infectious Uveitis in Q2 2024

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top